Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.
作者信息
Shafer Robert W, Nguyen Dong Phuong, Fessel W Jeffrey
机构信息
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
出版信息
MedGenMed. 2006 Aug 7;8(3):32.
Abstract
摘要
相似文献
1
2
Interpretation of resistance assay results.耐药性检测结果的解读。
Antivir Ther. 2001;6 Suppl 2:1-9.
3
4
Clinical utility of resistance testing.耐药性检测的临床应用
J HIV Ther. 2002 Nov;7(4):75-9.
5
Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.第八届逆转录病毒与机会性感染会议精选主题。2001年2月4日至8日。伊利诺伊州芝加哥。
HIV Clin Trials. 2001 May-Jun;2(3):219-26. doi: 10.1310/M79M-C5Q5-9ATV-1AM5.
6
[Resistance screening].[耐药性筛查]
MMW Fortschr Med. 2009 Apr 30;151(18):72, 74-5.
7
8
Antiretroviral resistance.抗逆转录病毒耐药性
J HIV Ther. 2006 Dec;11(4):72-3.
9
Current insights into reverse transcriptase inhibitor-associated resistance.逆转录酶抑制剂相关耐药性的当前见解。
Antivir Ther. 2001;6 Suppl 2:11-9.
引用本文的文献
本文引用的文献
1
2
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.基线和治疗相关因素对HIV-1阳性受试者开始抗逆转录病毒治疗后免疫恢复的影响：ACTG 384研究结果
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f.
3
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.抑制性抗逆转录病毒治疗期间CD4 + T细胞恢复的决定因素：免疫激活、T细胞成熟标志物与细胞内HIV-1 DNA的关联
J Infect Dis. 2006 Jul 1;194(1):29-37. doi: 10.1086/504718. Epub 2006 May 18.
4
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing.原发性HIV耐药性及耐药性检测指导下的一线抗逆转录病毒疗法的疗效
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):573-81. doi: 10.1097/01.qai.0000214805.52723.c1.
5
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.初治HIV感染患者是否应进行耐药性检测？一项成本效益分析。
Clin Infect Dis. 2005 Nov 1;41(9):1316-23. doi: 10.1086/496984. Epub 2005 Sep 23.
6
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.接受高效抗逆转录病毒治疗的1型HIV感染者中CD4 T细胞恢复至<500个细胞/微升的特征、决定因素及临床相关性
Clin Infect Dis. 2005 Aug 1;41(3):361-72. doi: 10.1086/431484. Epub 2005 Jun 24.
7
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.北美和欧洲原发性HIV耐药性的流行病学现状
Antivir Ther. 2004 Oct;9(5):695-702.
8
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.影响接受长期高效抗逆转录病毒治疗的HIV阳性患者CD4细胞计数增加的因素。
J Infect Dis. 2004 Nov 15;190(10):1860-8. doi: 10.1086/425075. Epub 2004 Oct 8.
9
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.215例开始接受含胸苷类似物的首次高效抗逆转录病毒治疗的HIV-1逆转者的治疗失败风险。
AIDS. 2004 Jan 23;18(2):227-35. doi: 10.1097/00002030-200401230-00012.
10
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.用于HIV-1感染初始治疗的序贯三联药物方案比较。
N Engl J Med. 2003 Dec 11;349(24):2293-303. doi: 10.1056/NEJMoa030264.
Zotero 插件